Preventive screening for intracranial aneurysms

Gabriel JE Rinkel and Ynte M Ruigrok

Abstract

Background: Subarachnoid hemorrhage from rupture of an intracranial aneurysm (aneurysmal subarachnoid hemorrhage) is a devastating subset of stroke. Since brain damage from the initial hemorrhage is a major cause for the poor outcome after aneurysmal subarachnoid hemorrhage, prevention of aneurysmal subarachnoid hemorrhage has the highest potential to prevent poor outcome from aneurysmal subarachnoid hemorrhage.

Aim: In this review, we describe the groups at high risk of aneurysmal subarachnoid hemorrhage who may benefit from preventive screening for unruptured intracranial aneurysms followed by preventive treatment of unruptured intracranial aneurysms found. Furthermore, we describe the advantages and disadvantages of screening and advise how to perform counseling on screening.

Summary of review: Modeling studies show that persons with two or more affected first-degree relatives with aneurysmal subarachnoid hemorrhage and patients with autosomal dominant polycystic kidney disease (ADPKD) are candidates for screening for unruptured intracranial aneurysms. One modeling study also suggests that persons with only one affected first-degree relative with aneurysmal subarachnoid hemorrhage are also likely candidates for screening. Another group who may benefit from screening are persons ≥35 years who smoke(d) and are hypertensive, given their high lifetime risk of aneurysmal subarachnoid hemorrhage of up to 7%, but the prevalence of unruptured intracranial aneurysms in such persons and the efficiency and cost-effectiveness of screening in this group are not yet known. The ultimate goal of screening is to increase the number of quality years of life of the screening candidates, and therefore the benefits but also many downsides of screening – such as risk of incidental findings, very small unruptured intracranial aneurysms that require regular follow-up, preventive treatment with inherent risk of complications and anxiety – should be discussed with the candidate so that an informed decision can be made before intracranial vessels are imaged.

Conclusions: Several groups of persons who may benefit from screening have been identified, but since these constitute only a minority of all aneurysmal subarachnoid hemorrhage patients, additional high-risk groups still need to be identified. Further research is also needed to identify persons at low or high risk of aneurysmal development and rupture within the groups identified thus far to improve the efficiency of screening. Moreover, if new medical treatment strategies that can reduce the risk of rupture of unruptured intracranial aneurysm become available, the groups of persons who may benefit from screening could increase considerably.

Keywords
Intracranial aneurysm, subarachnoid hemorrhage, screening, familial

Received: 28 April 2021; accepted: 25 May 2021
cognitive complaints or deficits that preclude resuming all pre-morbid activities. All in all, only 5% of patients can take up their pre-morbid life without any restrictions or complaints.\(^3\)

Since brain damage from the initial hemorrhage is a major cause for the poor outcome after ASAH,\(^3\) prevention of ASAH has the highest potential to prevent poor outcome from ASAH. IAs are hardly ever symptomatic before they rupture, and therefore screening is the only way to detect IAs before rupture, and to install preventive treatment. The purpose of screening is, however, not to detect IAs, or to prevent ASAH, but to improve the number of life years in good quality of life, and persons who seek advice on screening should be properly informed about the benefits, but also the risks of screening so that they can make an informed decision whether or not to undergo screening.

For medical interventions, the best available evidence are randomized clinical trials, or meta-analyses thereof. Such trials have never been done for screening of high-risk groups of ASAH, and the chance that such trials will ever be performed is small given the large number of persons that should participate in such trials, the decades of follow-up needed for such a trial, and last but not least the unlikeliness that a sufficient number of potential participants will agree to participate. Persons with a familial preponderance of ASAH are an important group of potential screening candidates, or trial participants, but if someone already has seen close relatives dying or being impaired from ASAH, the likelihood that someone agrees in no screening but regular follow-up is probably small. In the absence of randomized trials, modeling studies are a good alternative and therefore evidence that screening is useful therefore comes only from such studies.\(^5\) For such a modeling approach, data are needed on chances of finding an unruptured intracranial aneurysm (UIA) and of rupture of the aneurysm in the particular subgroup of persons, and on life expectancy, risk of complications from preventive aneurysm treatment, and level of anxiety in both the screened and non-screened persons. Modeling studies can also inform on the cost-effectiveness of screening strategies, a factor to be considered since screening and preventive treatment of UIAs come with costs.

In this review, we describe the high-risk groups for ASAH, the evidence for screening in these high-risk groups, the disadvantages of screening, and advise on how to counsel persons who seek advice on screening.

**High-risk groups**

*Familial intracranial aneurysms*

Persons with a positive family history for ASAH are the largest group of persons who may benefit from screening and preventive aneurysm treatment, since around 10% of all ASAH patients have a one or more relatives who also had an ASAH.\(^6,7\)

**Persons with two or more first-degree relatives with ASAH**

For persons with two or more affected first-degree relatives, the estimated lifetime risk of ASAH can be higher than 20%,\(^8\) depending on the type of relation and presence or absence of other risk factors (Table 1). The lifetime risk is higher for siblings than for parents or children of affected patients,\(^9\) and increases in persons who smoke or have hypertension.\(^10\)

The chance of finding an UIA at screening of a person with two or more affected relatives is around 10% at initial screening, and around 5–7% at follow-up screening with five-year intervals (Table 1).\(^11\) This chance is independent from the age of the screened person after the third decade of age. This means that the upper age limit of screening does not depend on the chance of finding an UIA, but on the balance between remaining life expectancy and risk of complications of preventive aneurysm treatment. Although women have a slightly higher chance of having an UIA than men if

| Number affected first-degree relatives | Chance of finding aneurysm at screening | Estimated life time risk of ASAH\(^a\) |
|---------------------------------------|----------------------------------------|--------------------------------------|
| 0                                     | 3.2% (95% CI 1.9–5.2)\(^48\)           | 0.5%\(^1\)                            |
| 1                                     | 4% (95% CI 2.6–5.8)\(^19\)             | 3–4%\(^8,49–50\)                     |
| 2 or more                             | 11% (95% CI 9–14)\(^11\)              | Up to 20%\(^8\)                      |

95% CI: 95% confidence interval.  
\(^a\)The estimates are based on the incidence rates and life expectancy numbers; accordingly no uncertainty levels can be calculated.
the affected relative is a woman, this difference is too small to take sex into account when counseling on screening.

The risk of rupture of familial aneurysms has long been considered very high. This was based on a relative risk of 17 found in a study comparing the risk of rupture found in the Familial Intracranial Aneurysm study with that of comparable aneurysms in the International Study of Unruptured Intracranial Aneurysm. Besides the indirect comparison between two cohorts of patients, other limitations of the study are the strict selection of patients with familial aneurysms: apart from having a positive family history, relatives should also have had a history of smoking, hypertension or both for inclusion in the study. Moreover, this high relative risk was based on only two instances of ASAH. Recent data from a single center study comparing familial and non-familial aneurysm indeed showed an increased rupture risk for familial aneurysm, but to a more modest level with a tripled risk.

Although familial aneurysms tend to rupture at younger age than sporadic aneurysms, there is no good concordance of age at time of rupture within families. Thus, age of the screened person found to have an aneurysm does not help to discriminate high- from low-risk aneurysms within families. Similarly, there is no good concordance in aneurysm size at rupture within familial IAs, which indicates that size of a ruptured IA in a family member should not influence the management of a familial UIA in a relative.

The high life-time risk of ASAH, the high chance of finding an UIA at screening and the increased risk of rupture of familial aneurysms all suggest that persons with two or more affected first-degree relatives are good candidates for screening. Indeed, two modeling studies have shown that screening is cost-effective in these circumstances with the optimal strategy being to screen every 5–7 years between ages 20 and 70–80 years of age.

**Persons with one first-degree relative with ASAH**

Persons with only one first-degree relative with ASAH have long been considered no good candidates for screening, based on a modeling study that showed an increased life expectancy but a reduced number of quality-adjusted life years (QALYs) after screening and preventive treatment of UIAs. This model was developed over 25 years ago, and since then additional factors that may influence the outcome of this model have become available. First, newer data have shown that the risk of ASAH in such persons is higher than presumed when the model was developed, with an estimated lifetime risk of 3–4%. This risk is considerably higher than the risk for persons with no affected relatives, which is around 0.5%, based on the incidence of ASAH in the general population (Table 1). Second, the risk of complications of preventive aneurysm occlusion has decreased over the last decades, not only through the advent of endovascular treatment but also through a lower risk of complications from surgical treatment. These data suggest that the balance on benefits and risks of screening might have changed in favor of screening. Indeed, a single more recent modeling study using current data showed that screening such persons can be cost-effective, with a threshold of €20,000 per QALY. The strategy with highest net health benefit was screening such persons twice, at ages 40 and 55. More frequent screening still increases health benefits, but at high additional costs. Some uncertainty remains regarding the cost-effectiveness because the ‘probability’ that screening is cost-effective for most strategies is around 50% and not above the 70% that is required to confirm with certainty that it is cost-effective. However, based on these data, we feel persons should be informed on the increased risk of ASAH, and counseling on screening should be offered.

**Persons with first-degree relatives with UIA**

Most studies thus far have focused on relatives with ASAH or have not discriminated between relatives with ASAH and relatives with UIAs. There are no good data on prevalence of UIA or risk of ASAH for persons who have one or more relatives with UIA, but no relatives with ASAH. Thus, for such persons the efficiency of screening is unknown, and we tend to discourage such persons from screening. For persons with one first-degree relative with ASAH and one or more relatives with UIA, we advise screening every five years, despite lacking evidence for this particular subset of persons.

**Autosomal polycystic kidney disease (ADPKD)**

ADPKD is an autosomal dominant hereditary disorder in which patients develop cysts in kidneys and sometimes liver. ADPKD patients have a high risk of hypertension and cardiovascular disease including UIA and ASAH. The estimated prevalence of UIA is 10%, which is higher in case of a positive family history for hemorrhagic stroke (no distinction made in type of hemorrhage, so not specific for ASAH alone) or UIA with a risk ratio of 2.3 (95% CI 1.6–3.4). ADPKD is most often caused by mutations in the genes PKD1 (in 78% of families) or PKD2 (in 15% of families). Up to 6% of ADPKD patients might die of ASAH. In a recent prospective series of 495 ADPKD patients, ASAH incidence was 2.0/1000
Rinkel and Ruigrok

patient-years, thus 20 times higher than in the general population. Although ASAH is common in patients with ADPKD, only 1% of all ASAH cases is attributable to ADPKD because ADPKD is relatively rare with a prevalence of 1/1000 individuals. ASAH occurs at a younger age in patients with ADPKD (median age 42.8 years) than in patients without ADPKD (median age 52.8 years). In addition, ASAH occurs from smaller aneurysms in patients with ADPKD than in patients without ADPKD (6.00 vs 8.00 mm). Two recent modelling studies show that preventive screening for UIA in patients with ADPKD is cost-effective, regardless of the presence of a positive family history. Repeated screening every five years is advised after a negative initial study, because of the 10% risk of a new ASAH in the first decade after the initial episode.

Other conditions associated with UIA and ASAH

Other conditions associated with UIA and ASAH include the rare, genetic connective tissue disorders type IV Ehlers-Danlos syndrome (vascular subtype), Marfan syndrome, Loeys-Dietz syndrome, and type IV Ehlers-Danlos, Loeys-Dietz syndrome, and FMD. In these disorders, the series describing UIA and ASAH are small, and the presence of UIA and ASAH cannot be made. Moreover, little is known about the rupture risk of aneurysms, or the complication risks of preventive treatment in patients with these specific conditions. This makes evidence-based advice not possible. Some experts from international consortia screening have, however, expressed the opinion that screening may be considered for type IV Ehlers-Danlos, Loeys-Dietz syndrome, and FMD.

Potential additional high-risk groups eligible for screening

A group who may also benefit from screening are persons ≥35 years of age who smoke(d) and are hypertensive given their high lifetime risk of aSAH of up to 7%. Together with the group of patients with a positive family history, this high-risk group constitutes 30% of all ASAH patients. Therefore, a third of all ASAH cases could potentially be prevented with an optimal preventive screening strategy in these two groups of high-risk individuals. However, the prevalence of UIAs in persons ≥35 years who smoke(d) and are hypertensive, and thus the efficiency and cost-effectiveness of screening in this group are not yet known.

Counseling on screening

The purpose of counseling is providing the screening candidate the information on benefits and risks of screening she/he needs to make an informed decision on whether or not to undergo screening. Important is that the person feels sufficiently informed to make a sound decision. As the ultimate goal of screening is to increase the number of quality years of life of the screening candidates, the risks and benefits of screening should be weighed, before intracranial vessels are imaged (Table 2). First, it is important that screening is performed only in patients without significant comorbidity as in case of co-morbidity the advantages of screening may not sufficiently outweigh its disadvantages. Magnetic-resonance angiography (MRA) can be used to screen for UIAs and has the advantages over CT angiography (CTA) that no contrast injection is needed and there is no radiation exposure. In case of contra-indications for MRA, such as claustrophobia or previously neurosurgical clipping treatment with the clips causing extensive artefact on MRA, CTA can be performed instead. The purpose of screening, i.e. preventing ASAH and consequently increasing the number of quality years of life in the future, should be discussed. Herewith it is important to realize that with repeated screening and preventive treatment of UIAs identified not all episodes of ASAH can be prevented. In rare instances, aneurysms can develop and rupture within the regular screening interval of five years. Moreover, the optimal age for screening, the chance of an ASAH and the yield of screening for the screening candidate need to be outlined. The need of repeated screening should also be mentioned. Possible disadvantages of screening should be discussed as well. These include the risk of complications in case of preventive treatment of an UIA found at screening and the risk of finding a small UIA that is still too small to be treated at that time and must be followed up for possible growth with follow-up imaging. If the screening candidate has children, he/she should be informed that if on screening an UIA is identified, his/her children also become eligible for screening. It should also be mentioned that there is a chance of incidental findings other than aneurysms, including an asymptomatic brain infarcts, menigioma, cavernoma or a hypophyseal adenoma. Last, the implications for driving and flying licenses and life insurance, which may differ by country, should be discussed. At the end of the consultation, it is up to the patient to make an informed decision whether or not to undergo screening. Sometimes, a follow-up consultation proves necessary to give a patient an opportunity to reflect on the decision or for further discussion or information. Finally, all patients, even those who decide not to be screened,
should be advised to stop smoking and have their blood pressure checked regularly because also in persons with familial risk or ADPKD, smoking and hypertension increase the risks for both aneurysm development and ASAH.44,46

Conclusions and future perspectives

Based on the data presented, persons with two or more affected first-degree relatives with ASAH and patients with ADPKD are candidates for screening for IA. Current data also suggest that screening increases the number of quality adjusted life years at acceptable costs in persons with only one first-degree relative with ASAH. We feel such persons should also be informed about the higher risk they have for ASAH and about the possibility of counseling for screening.

Given the downsides there are with screening, persons should be counseled before imaging is ordered. The purpose of counseling is to present all relevant data to persons in such a way that they can make a truly informed decision on whether or not they want to undergo screening. For the physician who counsels the screening candidate, the ultimate interest of the encounter is not whether or not to have convinced the screening candidate for the most appropriate decision according to the statistical model, but a patient who feels to have been able to make an informed decision.

Because the groups of persons who may benefit from screening constitute only a minority of all ASAH patients, additional high risk groups still need to be identified. Moreover, within the groups of persons identified to benefit from screening, the current screening strategies for these groups are still inefficient. Many persons undergo several cycles of screening without ever having an aneurysm, and some persons still have ASAH despite screening. Future research on genetics, including on rare genetic variants in familial aneurysms and genetic risk scores predicting UIA or ASAH, and on anatomical risk factors such as configuration of the circle of Willis, may identify persons at low or high risk of aneurysmal development and rupture within the groups identified thus far, which may render screening more efficient. Similarly, data on absolute risks of UIA or ASAH according to age, number of affected relatives, and environmental risk factors as smoking and hypertension may further discriminate low- from high-risk persons within the group of persons with a positive family history. Current treatment strategies for preventive aneurysm occlusion carry considerable risks, which reduce the benefit of screening. If new treatment strategies to reduce the risk of rupture of UIA, such as medical treatment with antihypertensive drugs and aspirin,47 become available, the groups of persons who may benefit from screening could increase considerably.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We acknowledge the support from the Netherlands Cardiovascular Research Initiative: An initiative with support of the Dutch Heart Foundation, CVON2015-08 ERASE. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 852173).

ORCID iD

Ynte M Ruigrok  https://orcid.org/0000-0002-5396-2989

References

1. Etminan N, Chang HS, Hackenberg K, et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage
according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. *JAMA Neurol* 2019; 76: 588–597.

2. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK and Rinkel GJE. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol* 2009; 8: 635–642.

3. Passier PE, Visser-Meily JM, van Zandvoort MJ, Post MW, Rinkel GJE and van Heugten C. Prevalence and determinants of cognitive complaints after aneurysmal subarachnoid hemorrhage. *Cerebrovasc Dis* 2010; 29: 557–563.

4. Vergouwen MD, Jong-Tijen-Fa AV, Algra A and Rinkel GJ. Time trends in causes of death after aneurysmal subarachnoid hemorrhage: a hospital-based study. *Neurology* 2015; 86: 59–63.

5. Schaufsma JD, van der Graaf Y, Rinkel GJE and Buskens E. Decision analysis to complete diagnostic research by closing the gap between test characteristics and cost-effectiveness. *J Clin Epidemiol* 2009; 62: 1248–1252.

6. Bromberg JEC, Rinkel GJE, Algra A, et al. Subarachnoid haemorrhage in first and second degree relatives of patients with subarachnoid haemorrhage. *BMJ* 1995; 311: 288–289.

7. Schievink WI, Schaid DJ, Michels VV and Piepgras DG. Familial aneurysmal subarachnoid hemorrhage: a community based study. *J Neurosurg* 1995; 83: 426–429.

8. Bor AS, Rinkel GJE, Adami J, et al. Risk of subarachnoid haemorrhage according to number of affected relatives: a population based case-control study. *Brain* 2008; 131: 2662–2665.

9. Zuurhier C, Greving JP, Rinkel G and Ruigrok YM. Higher risk of intracranial aneurysms and subarachnoid haemorrhage in siblings of families with intracranial aneurysms. *Eur Stroke J* 2020; 5: 73–77.

10. Vlak MH, Rinkel GJE, Grebee P, Greving JP and Algra A. Lifetime risks for aneurysmal subarachnoid hemorrhage: multivariable risk stratification. *J Neurol Neurosurg Psychiatry* 2013; 84: 619–623.

11. Bor AS, Rinkel GJE, van Norden J and Wermers MJ. Long-term, serial screening for intracranial aneurysms in individuals with a family history of aneurysmal subarachnoid haemorrhage: a cohort study. *Lancet Neurol* 2014; 13: 385–392.

12. Sijtsma LC, Rinkel GJ and Ruigrok YM. Sex-related clustering of intracranial aneurysms within families. *Stroke* 2015; 46: 1107–1109.

13. Broderick JP, Brown RD Jr, Sauerbeck L, et al. Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. *Stroke* 2009; 40: 1952–1957.

14. Mensing LA, Greving JP, Verhoef TA, Rinkel GJE and Ruigrok YM. Comparison of rupture risk of intracranial aneurysms between familial and sporadic patients. *Stroke* 2019; 50: 1380–1383.

15. Slot EMH, Rinkel GJE, Algra A and Ruigrok YM. Patient and aneurysm characteristics in familial intracranial aneurysms. A systematic review and meta-analysis. *PLoS One* 2019; 14: e0213372.

16. Bourcier R, Lindgren A, Desal H, et al. Concordance in aneurysm size at time of rupture in familial intracranial aneurysms. *Stroke* 2019; 50: 504–506.

17. Bor ASE, Koffijberg H, Wermers MJ and Rinkel GJE. Optimal screening strategy for familial intracranial aneurysms: A cost-effectiveness analysis. *Neurology* 2010; 74: 1671–1679.

18. Takao H, Nojo T and Ohtomo K. Screening for familial intracranial aneurysms decision and cost-effectiveness analysis. *Acad Radiol* 2008; 15: 462–471.

19. The Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group. Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. *N Engl J Med* 1999; 341: 1344–1350.

20. Rasing I, Ruigrok YM, Grebee P, et al. Long-term risk of aneurysmal subarachnoid hemorrhage after a negative aneurysm screen. *Neurology* 2015; 84: 912–917.

21. Algra AM, Lindgren A, Vergouwen MDI, et al. Procedural clinical complications, case-fatality risks, and risk factors in endovascular and neurosurgical treatment of unruptured intracranial aneurysms: a systematic review and meta-analysis. *JAMA Neurol* 2019; 76: 282–293.

22. Hopmans EM, Ruigrok YM, Bor AS, Rinkel GJ and Koffijberg H. A cost-effectiveness analysis of screening for intracranial aneurysms in persons with one first-degree relative with subarachnoid haemorrhage. *Eur Stroke J* 2016; 1: 320–329.

23. Cornec-Le Gall E, Alam A and Perrone RD. Autosomal dominant polycystic kidney disease. *Lancet* 2019; 393: 919–935.

24. Zhou Z, Xu Y, Delcourt C, et al. Is regular screening for intracranial aneurysm necessary in patients with autosomal dominant polycystic kidney disease? A systematic review and meta-analysis. *Cerebrovasc Dis* 2017; 44: 75–82.

25. Fick GM, Johnson AM, Hammond WS and Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 1995; 5: 2048–2056.

26. Flahault A, Trystram D, Nataf F, et al. Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. *Kidney Int* 2018; 93: 716–726.

27. Cornec-Le Gall E, Torres VE and Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. *J Am Soc Nephrol* 2018; 29: 13–23.

28. Nurmonen HJ, Huttunen T, Huttunen J, et al. Polycystic kidney disease among 4,436 intracranial aneurysm patients from a defined population. *J Am Soc Nephrol* 2017; 282–293.

29. Malhotra A, Wu X, Matouk CC, Forman HP, Gandhi D and Sanelly P. MR angiography screening and surveillance for intracranial aneurysms in autosomal dominant polycystic kidney disease: a cost-effectiveness analysis. *Radiology* 2019; 291: 400–408.
31. Nurmonen HJ, Huttunen T, Huttunen J, et al. Lack of impact of polycystic kidney disease on the outcome of aneurysmal subarachnoid hemorrhage: a matched case-control study. *J Neurosurg* 2020; 134: 1871–1878.

32. Kim ST, Brinjikji W and Kallmes DF. Prevalence of intracranial aneurysms in patients with connective tissue diseases: a retrospective study. *AJNR Am J Neuroradiol* 2016; 37: 1422–1426.

33. Kim ST, Cloft H, Flemming KD, Kallmes DF, Lanzino G and Brinjikji W. Increased prevalence of cerebrovascular disease in hospitalized patients with Ehlers-Danlos Syndrome. *J Stroke Cerebrovasc Dis* 2017; 26: 1678–1682.

34. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. *Am J Med Genet C Semin Med Genet* 2017; 175: 40–47.

35. Kim ST, Cloft H, Flemming KD, Kallmes DF, Lanzino G and Brinjikji W. Increased Prevalence of Cerebrovascular Disease in Hospitalized Patients with Marfan Syndrome. *J Stroke Cerebrovasc Dis* 2018; 27: 296–300.

36. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. *N Engl J Med* 2006; 355: 788–798.

37. MacCarrick G, Black JH 3rd, Bowdin S, et al. Loey-Dietz syndrome: a primer for diagnosis and management. *Genet Med* 2014; 16: 576–587.

38. Lather HD, Gornik HL, Olin JW, et al. Prevalence of intracranial aneurysm in women with fibromuscular dysplasia: a report from the US Registry for Fibromuscular Dysplasia. *JAMA Neurol* 2017; 74: 1081–1087.

39. Gornik HL, Persu A, Adlam D, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. *Vasc Med* 2019; 24: 164–189.

40. Yu X, Xia L, Jiang Q, Wei Y, Wei X and Cao S. Prevalence of intracranial aneurysm in patients with aortopathy: a systematic review with meta-analyses. *J Stroke* 2020; 22: 76–86.

41. Vlak MH, Rinkel GJ, Greepe P, Grevin JP and Algra A. Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification. *J Neurol Neurosurg Psychiatry* 2013; 84: 619–623.

42. Gonner F, Lovblad KO, Heid O, et al. Magnetic resonance angiography with ultrashort echo times reduces the artefact of aneurysm clips. *Neuroradiology* 2002; 44: 755–758.

43. Schievink WI, Limburg M, Dreissen JJ, Peeters FL and ten Berg HWM. Screening for unruptured familial intracranial aneurysms: subarachnoid hemorrhage 2 years after angiography negative for aneurysms. *Neurosurgery* 1991; 29: 434–437.

44. Etminan N and Rinkel GJ. Unruptured intracranial aneurysms: development, rupture and preventive management. *Nat Rev Neurol* 2016; 12: 699–713.

45. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. *N Engl J Med* 2007; 357: 1821–1828.

46. Rasing I, Nieuwkamp DJ, Algra A and Rinkel GJE. Additional risk of hypertension and smoking for aneurysms in people with a family history of subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry* 2012; 83: 541–542.

47. Vergouwen MD, Rinkel GJ, Algra A, et al. Prospective Randomized Open-label Trial to evaluate risk faCTor management in patients with unruptured intracranial aneurysms: study protocol. *Int J Stroke* 2018; 13: 992–998.

48. Vlak MH, Algra A, Brandenburg R and Rinkel GJE. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. *Lancet Neurol* 2011; 10: 626–636.

49. Raaymakers TWM; group Ms. Aneurysms in relatives of patients with subarachnoid hemorrhage. Frequency and risk factors. *Neurology* 1999; 53: 982–988.

50. Gaist D, Vaeth M, Tsiropoulos I, et al. Risk of subarachnoid haemorrhage in first degree relatives of patients with subarachnoid haemorrhage: follow up study based on national registries in Denmark. *BMJ* 2000; 320: 141–145.